dc.contributor.author
Pappritz, Kathleen
dc.contributor.author
Linthout, Sophie Van
dc.date.accessioned
2020-11-12T13:57:47Z
dc.date.available
2020-11-12T13:57:47Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/28774
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-28523
dc.description.abstract
Myocarditis is an inflammatory disorder of the heart predominantly caused by infectious agents. Since more than sixty years, the Coxsackievirus B3 (CVB3)-induced myocarditis mouse model is the experimental model used to investigate viral myocarditis. The pathogenesis of viral myocarditis is conceptually a multiphase process, initiated by the infection of cardiomyocytes, followed by activation of the immune system, and resulting in myocardial fibrosis and left ventricular dysfunction. In parallel to the direct infection of the heart, CVB3 replicates in lymphatic organs such as the pancreas. Due to infection of the pancreas, the model of experimental CVB3-induced myocarditis is estimated as a severe burden for the challenged animals. Application of analgesics in frame of the animal welfare act (European directive 2010/63/EU) is more and more becoming a matter of debate. For this purpose, we summarized published studies for 13 different opioids and discussed their potential impact on CVB3-induced myocarditis. In addition, with this summary we also want to provide guidance for researchers beyond the myocarditis field to estimate the impact of opioids on the immune system for their specific model. In the literature, both immunosuppressive as well as immune-activating effects of opioids have been described, but examinations in experimental CVB3-induced myocarditis have still not been reported so far. Based on the existing publications, administration of opioids in experimental CVB3-induced myocarditis might result in more severe disease progression, including higher mortality, or a less pronounced myocarditis model, failing to be used for the establishment of new treatment options. Taken together, the applicability of opioids in experimental CVB3-induced myocarditis and in inflammatory models in general needs to be carefully evaluated and further investigated.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
coxsackievirus B3 (CVB3)-induced myocarditis
en
dc.subject
immunomodulation
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Opioid-Induced Immunomodulation: Consequences for the Experimental Coxsackievirus B3-Induced Myocarditis Model
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
335
dcterms.bibliographicCitation.doi
10.3390/biology9100335
dcterms.bibliographicCitation.journaltitle
Biology
dcterms.bibliographicCitation.number
10
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
9
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33066118
dcterms.isPartOf.eissn
2079-7737